In vitro and ex vivo investigation of steroid containing ocular drug delivery systems by Bíró, Tivadar & Aigner, Zoltán
II. Symposium of Young Researchers on Pharmaceutical Technology, 
Biotechnology and Regulatory Science 




In vitro and ex vivo investigation of steroid containing ocular drug delivery 
systems 
Tivadar Bíró, Zoltán Aigner 
Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary 
 
The poor bioavailability in ocular drug delivery is well known, which is mostly caused by the 
special defensive mechanisms and complex anatomical structure of human eye. Possibilities 
are known for inducing enhanced therapeutic efficacy - due to increasing the solubility of drug 
and the residence time on the eye surface. Formulation specialists need to ensure not only 
the optimal drug permeation but also the required microbiological stability. The widely 
applied benzalkonium-chloride is toxic on the corneal epithelial cells, therefore use of 
alternative, nontoxic preservative agents is needed [1]. 
Cyclodextrin containing, mucoadhesive ocular drug delivery systems were optimized by our 
research group. Results of mucoadhesion, surface tension, viscosity, in vitro drug diffusion and 
antimicrobial effectiveness test were previously published [2]. Afterwards, in vitro toxicity and 
permeability were studied on human corneal epithelial cell line, and ex vivo drug permeability 
was tested using porcine corneal model. As the results show, toxicity and permeability are 
more suitable, than benzalkonium-chloride containing compositions or suspension forms. In 
summary, the prepared formulations could be innovative approaches for steroid containing 
eye drops with increased bioavailability. 
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